Cabaletta Bio Stock Performance
| CABA Stock | USD 1.67 0.01 0.60% |
On a scale of 0 to 100, Cabaletta Bio holds a performance score of 8. The firm shows a Beta (market volatility) of -0.55, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Cabaletta Bio are expected to decrease at a much lower rate. During the bear market, Cabaletta Bio is likely to outperform the market. Please check Cabaletta Bio's mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and total risk alpha , to make a quick decision on whether Cabaletta Bio's price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cabaletta Bio are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak fundamental drivers, Cabaletta Bio sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 193.2 M | |
| Total Cashflows From Investing Activities | 47.3 M |
Cabaletta | Build AI portfolio with Cabaletta Stock |
Cabaletta Bio Relative Risk vs. Return Landscape
If you would invest 117.00 in Cabaletta Bio on April 21, 2025 and sell it today you would earn a total of 50.00 from holding Cabaletta Bio or generate 42.74% return on investment over 90 days. Cabaletta Bio is currently generating 0.8551% in daily expected returns and assumes 7.8639% risk (volatility on return distribution) over the 90 days horizon. In different words, 70% of stocks are less volatile than Cabaletta, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cabaletta Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cabaletta Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cabaletta Bio, and traders can use it to determine the average amount a Cabaletta Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1087
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CABA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.86 actual daily | 70 70% of assets are less volatile |
Expected Return
| 0.86 actual daily | 17 83% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Cabaletta Bio is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cabaletta Bio by adding it to a well-diversified portfolio.
Cabaletta Bio Fundamentals Growth
Cabaletta Stock prices reflect investors' perceptions of the future prospects and financial health of Cabaletta Bio, and Cabaletta Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cabaletta Stock performance.
| Return On Equity | -0.74 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 47.17 M | ||||
| Shares Outstanding | 89.94 M | ||||
| Price To Earning | (3.33) X | ||||
| Price To Book | 1.24 X | ||||
| EBITDA | (125.14 M) | ||||
| Cash And Equivalents | 96.81 M | ||||
| Cash Per Share | 3.34 X | ||||
| Total Debt | 15.6 M | ||||
| Debt To Equity | (3.76) % | ||||
| Book Value Per Share | 2.40 X | ||||
| Cash Flow From Operations | (88.22 M) | ||||
| Earnings Per Share | (2.54) X | ||||
| Total Asset | 185.05 M | ||||
| Retained Earnings | (349.1 M) | ||||
| Current Asset | 30.42 M | ||||
| Current Liabilities | 843.74 K | ||||
About Cabaletta Bio Performance
By analyzing Cabaletta Bio's fundamental ratios, stakeholders can gain valuable insights into Cabaletta Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cabaletta Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cabaletta Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Cabaletta Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people.Things to note about Cabaletta Bio performance evaluation
Checking the ongoing alerts about Cabaletta Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cabaletta Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cabaletta Bio is way too risky over 90 days horizon | |
| Cabaletta Bio may become a speculative penny stock | |
| Cabaletta Bio appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (115.86 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cabaletta Bio currently holds about 96.81 M in cash with (88.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cabaletta Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 68.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Cabaletta Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cabaletta Bio's stock is overvalued or undervalued compared to its peers.
- Examining Cabaletta Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cabaletta Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cabaletta Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cabaletta Bio's stock. These opinions can provide insight into Cabaletta Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cabaletta Stock analysis
When running Cabaletta Bio's price analysis, check to measure Cabaletta Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cabaletta Bio is operating at the current time. Most of Cabaletta Bio's value examination focuses on studying past and present price action to predict the probability of Cabaletta Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cabaletta Bio's price. Additionally, you may evaluate how the addition of Cabaletta Bio to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |